Support is requested for predoctoral positions to establish a novel interdisciplinary training program in pharmacological sciences. The objective is to train leaders for academia, biotechnology/industrial firms, and regulatory agencies who will develop new innovations, approaches, and strategies for drug development and accelerate the rate of bringing new therapeutics to the market. Such leaders are essential if we are to reduce the enormous cost and length of time it currently takes to bring safe, effective agents to the public. The proposed training program is unique in several ways: (1) it spans the entire range of drug development from initial target identification and validation through FDA approval, (2) it is led by a PI and leadership team with extensive, first-hand experience in the pharmaceutical industry as well as academia, (3) it introduces a systems biology approach to achieving efficacy and safety by identifying and selectively modulating relevant pathways, rather than individual targets and addresses all major phases of the drug development process, and (4) it includes analyses of major successes and failures in the pharmaceutical industry and regulatory agencies. This proposal builds on a current Roadmap Training Grant that has established an effective organizational foundation for training in drug discovery and development at the Gulf Coast Consortia's Keck Center, an educational cooperative of 6 neighboring institutions - Baylor College of Medicine, M. D. Anderson Cancer Center, Rice University, University of Houston, The University of Texas Health Science Center at Houston, and The University of Texas Medical Branch at Galveston. The training faculty includes 55 members with broad research expertise and extensive training experience. Trainees will matriculate and receive first year support from their home institutions, and training grant stipends will be awarded on a competitive basis for years 2-3 of graduate training. Training will involve didactic courses, seminars, drug development team tutorials, retreats, and career development activities. These will be open to all pre- and postdoctoral trainees at the 6 institutions, and they may obtain a Certificate in Pharmacological Sciences by participating, which will greatly increase the program's impact. The home institution will award the Ph.D.

Public Health Relevance

This program will train future leaders for universities, the pharmaceutical industry, and government regulatory agencies in the entire process - from basic laboratory discoveries through government approval - of providing safe, effective new drugs to the public. These leaders will decrease the current unacceptably high cost, length of time, and number of side effects now associated with developing new drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
1T32GM089657-01A1
Application #
7941349
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Okita, Richard T
Project Start
2010-07-01
Project End
2015-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
1
Fiscal Year
2010
Total Cost
$111,684
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Type
Schools of Medicine
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Ali, Syed R; Liu, Zhiqing; Nenov, Miroslav N et al. (2018) Functional Modulation of Voltage-Gated Sodium Channels by a FGF14-Based Peptidomimetic. ACS Chem Neurosci 9:976-987
Campbell, James C; VanSchouwen, Bryan; Lorenz, Robin et al. (2017) Crystal structure of cGMP-dependent protein kinase I? cyclic nucleotide-binding-B domain : Rp-cGMPS complex reveals an apo-like, inactive conformation. FEBS Lett 591:221-230
Li, Yong; Baldwin, Tanya A; Wang, Yan et al. (2017) Loss of type 9 adenylyl cyclase triggers reduced phosphorylation of Hsp20 and diastolic dysfunction. Sci Rep 7:5522
Campbell, James C; Henning, Philipp; Franz, Eugen et al. (2017) Structural Basis of Analog Specificity in PKG I and II. ACS Chem Biol 12:2388-2398
Ma, Junyan; Yanez-Orozco, Inna S; Rezaei Adariani, Soheila et al. (2017) High Precision FRET at Single-molecule Level for Biomolecule Structure Determination. J Vis Exp :
Ali, Syed R; Singh, Aditya K; Laezza, Fernanda (2016) Identification of Amino Acid Residues in Fibroblast Growth Factor 14 (FGF14) Required for Structure-Function Interactions with Voltage-gated Sodium Channel Nav1.6. J Biol Chem 291:11268-84
Ding, Ye; Ding, Chunyong; Ye, Na et al. (2016) Discovery and development of natural product oridonin-inspired anticancer agents. Eur J Med Chem 122:102-117
Campbell, James C; Tischer, Alexander; Machha, Venkata et al. (2016) Data on the purification and crystallization of the loss-of-function von Willebrand disease variant (p.Gly1324Ser) of the von Willebrand factor A1 domain. Data Brief 7:1700-1706
Liu, Zhiqing; Ding, Ye; Ye, Na et al. (2016) Direct Activation of Bax Protein for Cancer Therapy. Med Res Rev 36:313-41
Liu, Zhiqing; Wild, Christopher; Ding, Ye et al. (2016) BH4 domain of Bcl-2 as a novel target for cancer therapy. Drug Discov Today 21:989-96

Showing the most recent 10 out of 34 publications